SCHEMBL5166235

SCHEMBL5166235

Nc1nc(-c2cc(-c3cnccn3)ccc2O)cn(C2CCCNC2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.40
CDK2 P24941 3/20 0.40
CHEK1 O14757 2/20 0.40
CCNA2 P20248 1/20 0.40
CCNA1 P78396 1/20 0.40
MET P08581 1/20 0.37
FLT3 P36888 1/20 0.37
RPLP1 P05386 1/20 0.37
RPLP0 P05388 1/20 0.37
RPS17 P08708 1/20 0.37
RPSA P08865 1/20 0.37
RPS2 P15880 1/20 0.37
RPL35A P18077 1/20 0.37
RPL7 P18124 1/20 0.37
RPL17 P18621 1/20 0.37
RPS4Y1 P22090 1/20 0.37
RPS3 P23396 1/20 0.37
RPS12 P25398 1/20 0.37
RPL13 P26373 1/20 0.37
RPL10 P27635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5166973 0.89 IKBKB (0.40) PRKCICDK2IKBKBCHUKABL1
SCHEMBL5164173 0.88 CHEK1 (0.44) PRKCICDK2CHEK1CCNA2CCNA1
SCHEMBL5164962 0.88 IKBKB (0.38) PRKCICDK2CHEK1CCNA2CCNA1
SCHEMBL5166876 0.86 PRKCI (0.38) PRKCICDK2CCNT1CCNE1CDK9
SCHEMBL5165078 0.85 IKBKB (0.36) PRKCICDK2CHEK1CCNA2CCNA1
SCHEMBL5166766 0.85 IKBKB (0.36) PRKCICDK2CHEK1GSK3BDYRK1A
SCHEMBL5166222 0.85 IKBKB (0.42) CDK2CHEK1CCNA2CCNA1HDAC1
SCHEMBL5164348 0.84 IKBKB (0.36) PRKCICDK2CHEK1IKBKBCHUK
SCHEMBL5166332 0.84 IKBKB (0.38) PRKCICDK2CHEK1IKBKBCHUK
SCHEMBL5166226 0.84 IKBKB (0.37) PRKCICDK2IKBKBCHUKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US claimed
EP-1678164-B1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-04-11 EP claimed
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US disclosed
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US disclosed
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation PFIZER INC. 2007-09-27 US disclosed
EP-1678164-B1 SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225291-A1 Substituted Pyrazinone Compounds for the Treatment of Inflammation CNKSR1, IL1RN, CHUK PRKCI 1363/4885CDK2 159/4885CHEK1 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.